Using the Mexican approach to conduct nonablative stem cell transplantation (NST), we have prospectively performed 58 allografts in individuals with various malignant and nonmalignant hematological diseases using sibling donors, either HLA identical (6/6) or compatible, with one mismatch (5/6). When comparing allografts obtained from HLA identical (n ¼ 40) or compatible (n ¼ 18) siblings, respectively, the overall median survival was found to be 33 vs 8 months (Po0.01), the 52-month survival was 47 vs 38% (P40.2), the prevalence of acute graft-versus-host disease (GVHD) 57 vs 38%, that of chronic GVHD 25 vs 11% and the relapse rate 45 vs 55%. The two patients who failed to engraft were both 5/6 matches. Probably stemming from the low number of patients, and despite a trend toward worse results in patients allografted from HLA compatible (5/6) siblings, most differences in outcome were not significant. It seems that NST can be offered to individuals with either an HLA identical or a compatible sibling donor.
matched; mismatched; outcome; sibling Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning is a valid treatment for a number of malignant and nonmalignant bone marrow disorders. 1, 2 The standard high-dose conditioning regimen has a considerable transplant-related mortality as well as a high incidence graft-versus-host disease (GVHD). Several groups of investigators have developed reduced-intensity, lymphoablative, conditioning regimens for allografting, without the toxicities of intense myeloablative conditioning. [3] [4] [5] [6] [7] In 1999, we started a prospective study of nonmyeloablative stem cell transplantation (NST) 8 using a conditioning regimen, which employs busulfan, fludarabine and cyclophosphamide. [9] [10] The method has been found to be useful to allograft individuals with different diseases and is endowed with several features, which make it attractive for use in developing countries: it is considerably cheaper than conventional allografting, 11, 12 can be conducted on an outpatient basis and without special areas within a hospital, [8] [9] [10] the transfusion requirements are very low, 13 the complication of cytomegalovirus (CMV) disease is very infrequent 14, 15 and the number of apheresis procedures in the donor can be reduced in order to obtain enough hematopoietic stem cells. 10 As a result of these features, allogeneic hematopoietic stem cell transplantation can be offered now to more patients as a therapeutic option, this observation being critical for individuals living in countries with limited resources; the fact that over twothirds of the inhabitants of the world live in developing countries should not be underestimated. 2, 10 Using the Mexican approach to conduct NST, 9 we have successfully allografted individuals with various malignant and nonmalignant hematological diseases [7] [8] [9] [10] [11] [13] [14] [15] [16] [17] using sibling donors, either HLA identical (6/6) or compatible with one mismatch (5/6) . We analyze herein the outcome of patients grafted from identical or compatible siblings as far as survival, relapse and features of GVHD are concerned.
Material and methods

Patients and donors
All the patients allografted in the Centro de Hematologı´a y Medicina Interna de Puebla (Puebla, Mexico) after January 1999 were prospectively accrued in the study. Serological typing for HLA-A and -B loci was used until 2002; subsequently, molecular hybrid capture typing was used for these loci. Class II DR antigens were studied always by molecular biology. C locus studies were not performed in all individuals. Donors and recipients needed to be matched at the HLA-A, -B and DR loci to be considered HLA identical; the donor was a matched sibling in all cases, either HLA compatible with one mismatch (5/6) or identical (6/6). Table 1 shows some of the patients' characteristics. All patients had a Karnofsky score of 100% when the procedure was performed. Institutional review board approval and written consent was obtained from all the individuals.
HSC mobilization and apheresis
Filgrastim, G-CSF (10 mg/kg/day) was delivered to the sibling donors on day À5 to þ 2. The apheresis procedures were performed on days 0, þ 1 and þ 2, according to the cell counts, by means of a Haemonetics V-50 PLUS machine (Haemonetics Corporation, Braintree, MA, USA) or a Baxter C-3000 PLUS machine (Baxter Healthcare, Deerfield, IL, USA), using the Spin-Nebraska protocol. 18 A measure of 5000-7000 ml of blood/m 2 were processed in each of the apheresis procedures, in order to obtain a minimum of 5 Â 10 8 mononuclear cells (MNC) and/or 2-6 Â 10 6 viable CD34 cells/kg of the recipient.
Enumeration of the total white blood, MNC and CD34-positive cells was carried out by flow cytometry 19, 20 in an EPICS Elite ESP apparatus (Coulter Electronics, Hialeah, FL, USA), using the anti-CD34 monoclonal antibody HPCA-2 20 (Becton Dickinson, San Jose´, CA, USA). No purging procedures were performed.
Conditioning and grafting
The Mexican NST conditioning regimen was used: [7] [8] [9] [10] [11] [13] [14] [15] [16] [17] it is a simplification of the low-intensity conditioning regimens used in Houston by Giralt et al were used in all patients; antibiotics and antimycotics were used until more than 500 granulocytes/ml were present. The products of the PBSC apheresis were reinfused as outpatients on days 0 to 2, according to the CD34 cell yield (vide supra).
Molecular biology studies
In cases with a sex mismatch, a fluorescent in situ hybridization technique to demonstrate the X and Y chromosomes was performed, 21, 22 whereas restriction fragment length polymorphism 22, 23 studies in the peripheral blood lymphocytes were used in the other cases. The molecular markers of the underlying disease (BCR/ABL-, PML/RARa-and AML1/ETO-specific transcripts) were detected by multiplex RT-PCR. 24 These studies were conducted at diagnosis, at 15, 30 and 60 days after the allograft and every 2-6 months afterwards. 22 
Results
In all, 58 consecutive allografts were prospectively included in the study. Table 1 shows the salient data of these patients grouped into two subsets: those with a 6/6 match and those with one mismatch (5/6): (a) 6/6 matches: 40 allografts were performed in 36 patients, their diagnosis and salient features being included in Table 1 . The overall median survival (SV) of this group was 33 months, with a 53-month SV of 47%. The prevalence of acute GVHD (aGVHD) was 57%, whereas that of chronic GVHD (cGVHD) was 25%. The relapse rate in this group was 45%; most relapsed patients had acute lymphoblastic leukemia (ALL, 11 cases). All patients engrafted successfully. (b) 5/6 matches: 18 allografts were performed in 16 patients (see Table 2 ). The overall median SV of this group was 8 months, with a 53-month SV of 38%. The prevalence of aGVHD was 38 %, whereas that of cGVHD was 11%. The relapse rate in this group was 55%; most relapsed patients also had ALL (four cases). Two patients in this subset failed to engraft. Figure 1 depicts the overall SV plots of these two groups of patients.
Discussion
Allogeneic bone marrow transplantation from HLA-mismatched donors is an alternative for patients who do not have a fully matched sibling donor. [25] [26] [27] [28] [29] [30] [31] It has been the practice of this center to use one-antigen HLA-mismatched donors for patients with both standard-and high-risk disease using the same NST conditioning regimen and GVHD prophylaxis as their counterparts from HLAidentical sibling donors. Anasetti et al 32 found that overall SV was not compromised in the 119 recipients of oneantigen HLA-mismatched BMT when compared to a cohort of 967 recipients of HLA-matched sibling transplants. The increased mortality from GVHD and graft failure seemed to be offset by a lower relapse rate in these patients. Most of the patients reported by Anasetti et al 32 received MTX and prednisone for GVHD prophylaxis and all had total body irradiation (TBI)-based conditioning regimens. On the other hand, Ottinger et al 33 found equivalent overall SV in the 37 recipients of one-antigen HLA-mismatched transplant when a matched pair analysis was performed. Interestingly, no difference in GVHD was noted between the two groups, although the overall incidence of GVHD was low. All patients in this study received short-course MTX and CyA for GVHD prophylaxis and all but one patient had TBI-based conditioning. 33 In contrast, several smaller studies have shown an adverse outcome with single antigen-mismatched transplants. 34, 35 These studies, however, had single HLA-mismatched groups that were too small to be appropriate for subgroup analysis. In a recent study, Hasegawa et al 36 found that the overall SV of one HLA-mismatched sibling transplant patients was inferior to that of HLA-identical sibling transplant patients; the patient population in this group was older and included more standard risk disease compared to patients in previous studies. In addition, all patients in this study received identical GVHD prophylaxis with CyA and MTX, and 57% of patients received TBIcontaining preparative regimens, both previous studies having used TBI-containing regimens exclusively.
However, up to now, there are no series of patients analyzed according to HLA compatibility, allografted using NST and the same GVHD prophylaxis with CyA and MTX. Our data show that the long-term overall SV of those patients with a perfect (6/6) match was better than that of patients with a single HLA locus mismatch (5/6): when comparing allografts obtained from HLA identical (n ¼ 40) or compatible, with one mismatch, (n ¼ 18) siblings, respectively, the overall median SV was 33 vs 8 months (Po0.01), the 52-month SV was 47 vs 38% (P40.2), the prevalence of aGVHD 57 vs 38%, that of cGVHD 25 vs 11% and the relapse rate 45 vs 55%. In the group of patients with a 5/6 match, most early deaths were due to relapse of the malignancy, which in two cases were blast phases of chronic myelogenous leukemia (CML). The two patients who failed to engraft were 5/6 matches. As we have shown previously for our allografting method, the best results of our program have been obtained in CML, whereas the worse in ALL: these differences may be related with the susceptibility of the malignancy to the graftversus-tumor effect: it is now clear that certain neoplasias such as CML are very sensitive to this effect, whereas ALL and other malignancies are less susceptible to this immune effect. 16, 37 Probably due to the low number of patients, no differences were found in the locus mismatch distribution between patients developing or not GVHD; by the same token, and despite a trend toward worse results in patients allografted from HLA compatible siblings, most differences in outcome were not significant. It seems that NST can be offered to individuals with either an HLA-identical or compatible sibling.
